Vertex Pharmaceuticals Inc
VRTX
View Detailed Chart
477.910USD
+3.740+0.79%
Close 01/28, 16:00（ET）Quotes delayed by 15 min
121.37BMarket Cap
33.40P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.79%
5 Days
+3.64%
1 Month
+3.24%
6 Months
+3.71%
Year to Date
+5.42%
1 Year
+8.45%
View Detailed Chart
TradingKey Stock Score of Vertex Pharmaceuticals Inc
Currency: USD Updated: 2026-01-28Key Insights
Vertex Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 503.63.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vertex Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Vertex Pharmaceuticals Inc Highlights
StrengthsRisks
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.40% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 33.40, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 248.51M shares, decreasing 2.74% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 5.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.81.
Analyst Rating
Based on
33
analysts
Buy
Current Rating
503.632
Target Price
+7.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vertex Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vertex Pharmaceuticals Inc Info
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Ticker SymbolVRTX
CompanyVertex Pharmaceuticals Inc
CEOKewalramani (Reshma)
Websitehttps://www.vrtx.com/
Related Instruments
-1.51%
+1.46%
-2.35%
-2.49%
-2.86%
-0.95%
-4.07%
-2.59%
-0.89%
-2.42%
-3.62%
-1.69%
-0.91%
-1.38%
-1.06%
-2.61%
0.00%
-2.42%
-1.30%Popular Symbols
256.440
-1.830 (-0.71%)
191.520
+3.000 (+1.59%)
88091.920
-1008.710 (-1.13%)
279.700
+27.040 (+10.70%)
2935.490
-74.210 (-2.47%)
431.460
+0.560 (+0.13%)
5537.840
+161.240 (+3.00%)
64.523
+1.306 (+2.07%)
1.196
+0.001 (+0.11%)
153.260
-0.117 (-0.08%)
